Huahai Pharmaceutical secures bids for four products in national procurement

Zhejiang Huahai Pharmaceutical Co., Ltd. participated in the eleventh national centralized drug procurement from October 27-28, 2025, with four of its products slated for successful bids. The procurement period for these products is set from the effective date of the bid results until December 31, 2028. This move is expected to facilitate rapid market penetration and boost the company's brand influence.

The products include Dopabas Dopa-Benserazide Tablets, priced at CNY 17.52 per box/bottle, and Agomelatine Tablets, priced at CNY 8.4 per box/bottle. Dopabas, approved in February 2024, generated approximately CNY 16.2047 million in domestic sales for 2024, representing 0.17% of the company's annual revenue. For the first half of 2025, sales reached CNY 14.3709 million, accounting for 0.32% of half-year revenue. Agomelatine, approved in March 2025, has not yet generated sales as of the first half of 2025.

Additionally, Nicergoline Tablets, priced at CNY 8.95 per box/bottle, and Metformin Hydrochloride and Empagliflozin Tablets (I), priced at CNY 8.96 per box/bottle, also secured bids. Nicergoline, approved in June 2025, has no sales as of mid-2025. Metformin Hydrochloride and Empagliflozin Tablets (I), approved in December 2024, recorded approximately CNY 0.3204 million in sales for the first half of 2025, constituting 0.0071% of the company’s half-year revenue. While these successful bids offer market opportunities, the reduced prices compared to original values, coupled with policy and market uncertainties, introduce an element of risk to future performance.